Esta web utiliza cookies para mejorar la experiencia del usuario. Puede obtener más información acerca del uso de cookies en el apartado Sobre las Cookies. Incluye instrucciones sobre cómo desconectarlas, si lo desea. Continuar navegando por el sitio web implica la aceptación del uso de cookies, como se describe en el apartado Sobre las Cookies.
Scolaris Content Language Banner PortletScolaris Content Language Banner Portlet
El idioma de tu navegador es inglés.
Elige el idioma que prefieras para las Revisiones Cochrane en la parte superior de cualquier página. Cambiar a inglés.
Scolaris Content DisplayScolaris Content Display
Anti‐angiogenic therapy for lung cancer
Referencias
Additional references
BMJ 1995
Non‐small Cell Lung Cancer Collaborative Group. Chemotherapy in non‐small cell lung cancer: A meta‐analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal 1995;311:899‐909.
Dvorak HF. Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumour Angiogenesis and a Potential Target for Diagnosis and Therapy. Journal of Clinical Oncology 2002;20(21):4368‐80.
Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions. Journal of Clinical Oncology 2005;23(6):1295‐311.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non Small‐Cell Lung Cancer Previously Treated With Chemotherapy. Journal of Clinical Oncology 2004;22(9):1589‐97.
Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8.5 The Cochrane Collaboration's tool for assessing risk of bias. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Kerbel 2002
Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Reviews. Cancer 2002;2(10):727‐39.
Kumar S, Witzig TE, Rajkumar SV. Thalidomide: Current Role in the Treatment of Non‐Plasma Cell Malignancies. Journal of Clinical Oncology 2004;22(12):2477‐88.
Parmar MK, Torri V, Stewart L. Extracting summary statistics toperform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Peterson P, Park K, et al. Is pemetrexed more effective in patients with non‐squamous histology. A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non small cell lung cancer (NSCLC). European Journal of Cancer 2007;5 (S363):6521.
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, et al. American Society of Clinical Oncology Treatment of Unresectable Non‐Small Cell Lung Cancer Guideline: Update 2003. Journal of Clinical Oncology 2004;22 (2):330‐53.
Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using Pubmed. International Journal of Epidemiology 2002;31(1):150‐3.
Scagliotti G, Purvish P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). Journal of Thoracic Oncology 2007;2 (8 Supp 4):S306 (PRS‐03).
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non‐small cell lung cancer. New England Journal of Medicine 2002;346(2):92‐8.
Todos los apartados aparecen seleccionados por defecto, por favor, seleccione los apartados que no desea imprimir o utilice el botón de seleccionar o deseleccionar todo para añadir o quitar apartados.
Seleccionar/deseleccionar todo
Los datos disponibles están protegidos por derechos de autor y sólo pueden utilizarse de acuerdo con los Términos y Condiciones.